Drug intelligence / Profile preview

benzylpenicillin + ceftriaxone + meropenem + piperacillin + tazobactam

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Intravenous, Intramuscular

Overview

This combination involves **benzylpenicillin** (a penicillin antibiotic), **ceftriaxone** (a cephalosporin antibiotic), **meropenem** (a carbapenem antibiotic), and **piperacillin + tazobactam** (a combination penicillin antibiotic with a beta-lactamase inhibitor). Each component works by inhibiting bacterial cell wall synthesis, thereby preventing bacterial growth and proliferation. Benzylpenicillin and ceftriaxone are effective against gram-positive bacteria, while meropenem and piperacillin + tazobactam have broader spectrums, including gram-negative bacteria.

Targets

NeuraminidasePBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on benzylpenicillin + ceftriaxone + meropenem + piperacillin + tazobactam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on benzylpenicillin + ceftriaxone + meropenem + piperacillin + tazobactam.

Explore the full profile